MariTide for weight loss means maridebart cafraglutide, Amgen's investigational once-monthly GLP-1/GIP injection that still has no FDA approval as of 2026 and cannot legally be prescribed outside a clinical trial. Adults who want fewer injections a year have three FDA-approved options to start now, and a MariTide timeline that still depends on unfinished Phase 3 data.
TL;DR
- MariTide for weight loss is investigational in 2026: maridebart cafraglutide has no FDA approval and cannot be prescribed.
- Amgen's Phase 2 data showed up to 20% weight loss at 52 weeks in adults without type 2 diabetes.
- Approved weekly injectables (Wegovy, Zepbound) and Foundayo, a daily oral GLP-1, are the only prescribable options right now.
- GoodLife Health's Cardiometabolic Optimization Membership pairs any approved GLP-1 with a Biomarker Audit every 90 days, billed at pharmacy cost.
- Waiting for once-monthly dosing means delaying treatment with no confirmed approval date attached to it.
Why once-monthly injections matter for adults done with weekly shots
Weekly GLP-1 injections work. The compliance burden is what wears people down: 52 refills a year, a titration schedule that shifts every four weeks, and a needle on the calendar every Sunday whether you feel like it or not. MariTide's whole appeal is arithmetic. Twelve injections a year instead of fifty-two.
That arithmetic matters more to some adults than others. Someone managing weight, insulin resistance, and inflammation as one connected system cares less about injection count and more about whether ApoB, HbA1c, and hs-CRP actually move between labs. GoodLife Health built its Cardiometabolic Optimization Membership around that second question, and it doesn't change whether the injection happens weekly or monthly.
Adults searching for once-monthly weight loss injections in 2026 are almost always asking about one specific drug, because no other branded GLP-1 or GIP therapy dosed less often than weekly has FDA approval yet.
What "once-monthly weight loss injection" actually means in 2026
MariTide, Amgen's maridebart cafraglutide, combines GLP-1 receptor agonism with GIP receptor antagonism, the opposite GIP mechanism from tirzepatide, which activates that same receptor. It is dosed as a monthly subcutaneous injection and has moved from Phase 2 into Phase 3 trials as of 2026, but Phase 3 completion and FDA review still stand between the drug and a pharmacy shelf.
Confirm where MariTide actually stands in 2026
Start here before you build a plan around a drug you can't get yet.
- Maridebart cafraglutide is Amgen's investigational once-monthly candidate, not an FDA-approved medication in 2026.
- Phase 2 data reported in 2024 showed weight loss up to 20% at 52 weeks in participants without type 2 diabetes.
- Phase 3 trials were still active as of 2026, with no confirmed FDA submission or approval date.
- MariTide is not available through any legitimate prescriber outside an active Amgen clinical trial.
- No compounded or "peptide" version of MariTide is legal, since it isn't even an approved molecule yet.
Get baseline biomarkers before you commit to any GLP-1
Whichever drug you end up on, the labs that predict how you'll respond don't change.
- HbA1c and fasting insulin, to see how much of your weight is driven by insulin resistance.
- A full lipid panel plus ApoB and Lp(a), since GLP-1 therapy shifts cardiovascular risk markers.
- hs-CRP, to flag inflammation that tracks with metabolic syndrome.
- A full thyroid panel, because undiagnosed hypothyroidism blunts weight loss on any medication.
- A complete hormone panel if you're over 40, since perimenopause and andropause both slow GLP-1 response.
Compare the injectable options you can actually start this month
MariTide isn't on the table in 2026. These are.
!Hand holding an injector pen next to a blank wall calendar
Weekly and monthly dosing are a scheduling difference, not a different result.
- Semaglutide (Wegovy): weekly injection, the most studied GLP-1 with cardiovascular outcomes data.
- Tirzepatide (Zepbound): weekly injection, dual GLP-1/GIP agonist, typically higher average weight loss than semaglutide alone.
- Orforglipron (Foundayo): once-daily oral tablet, no needle at all, for adults who want fewer injections rather than a slower schedule.
- Read the tirzepatide vs semaglutide comparison before picking a starting drug. The two aren't interchangeable.
Ask any clinician exactly how they bill the medication
This is where the frequency question turns into a cost question, and it's the step most adults skip.
GoodLife Health's Cardiometabolic Optimization Membership runs one flat $299 a month after a $598 two-month start, and every GLP-1 prescription, whether it's Wegovy, Zepbound, Ozempic, Mounjaro, or Foundayo, is billed by the pharmacy at pharmacy cost. No markup when the dose escalates, no per-molecule upcharge. That's the model to compare against, whatever clinic you're evaluating.
- Ask whether the fee changes as your dose increases. Many clinics reprice at each titration step.
- Ask whether labs are included or billed separately per draw.
- Ask who actually reads the labs: a clinician, or an algorithm.
- Ask if the price changes if you switch from semaglutide to tirzepatide later.
- Ask what happens to your membership if you want to pause an injection month.
Track labs and side effects on a fixed schedule
Whatever drug and whatever frequency, the schedule matters more than the drug.
- Recheck weight, waist circumference, and blood pressure monthly regardless of injection frequency.
- Repeat a comprehensive biomarker panel roughly every 90 days. GoodLife Health's Biomarker Audit runs on this cadence.
- Log GI side effects weekly during the first three months. They cluster during dose titration.
- Flag any new joint pain or unusual fatigue, since rapid weight loss can mask other issues.
- Recheck thyroid and hormone panels at six months if you started with a borderline result.
Decide: start now and switch later, or wait for MariTide
Waiting for MariTide because it might mean fewer injections a year is a bet on a Phase 3 program and an FDA review with no fixed date attached to it in 2026.
Adults who start an approved GLP-1 now and later want to move to MariTide, if and when it clears FDA review, aren't locked into anything. Starting now costs you nothing you weren't already losing by waiting.
Comparing your real options in 2026
| Option | Dosing frequency | Best for | Key limitation | Verdict |
|---|---|---|---|---|
| Semaglutide (Wegovy) | Weekly injection | Adults who want the most studied weekly GLP-1 with cardiovascular outcomes data | Still a weekly injection; appetite effects vary by dose | Buy |
| Tirzepatide (Zepbound) | Weekly injection | Adults who want a dual GIP/GLP-1 mechanism and typically stronger average weight loss | Weekly injection; GI side effects during titration | Buy |
| Orforglipron (Foundayo) | Once-daily oral tablet | Adults who want to avoid injections entirely | Daily pill, not once-monthly; still requires titration | Buy |
| Maridebart cafraglutide (MariTide) | Investigational once-monthly injection | Adults specifically prioritizing the lowest injection frequency, once approved | Not FDA-approved; unavailable outside Amgen's trials; no confirmed 2026 approval date | Wait |
!Two-column chart comparing GLP-1 options available now against MariTide still in trials
Only one row in this chart has a confirmed FDA approval in 2026.
Common mistakes adults make chasing once-monthly weight loss injections
- Waiting on treatment instead of starting now. Every month spent waiting for MariTide is a month without moving ApoB, HbA1c, or weight, and there's no confirmed date to wait for.
- Assuming monthly dosing means milder side effects. Trial data on MariTide's tolerability at monthly intervals is still developing; frequency alone doesn't predict how a GI side-effect profile behaves.
- Looking for compounded MariTide or gray-market "peptide" versions. Maridebart cafraglutide isn't an approved molecule, so nothing sold outside Amgen's trial is a legitimate or safe version of it.
- Skipping baseline labs because "it's just a weight loss shot." ApoB, HbA1c, and hormone panels change how a clinician doses and monitors any GLP-1, not just MariTide.
- Not asking how the pharmacy bills a dose increase. Dose-escalation repricing is common enough in this category that it deserves a direct question before you sign anything.
FAQ
What is MariTide for weight loss?
MariTide is Amgen's name for maridebart cafraglutide, an investigational once-monthly injection combining GLP-1 receptor agonism with GIP receptor antagonism. It is not FDA-approved in 2026 and cannot legally be prescribed outside a clinical trial.
Is MariTide FDA-approved in 2026?
No. MariTide remains in Phase 3 trials as of 2026, with no confirmed FDA submission or approval date. Any source offering it for sale outside a trial is not legitimate.
When will MariTide be available for weight loss?
There's no confirmed timeline. Amgen's Phase 3 program was still enrolling and reporting data through 2026, and FDA review typically adds months after a completed submission.
How does MariTide compare to Zepbound and Wegovy?
MariTide's mechanism differs from both: it blocks the GIP receptor rather than activating it, the opposite of tirzepatide (Zepbound), while semaglutide (Wegovy) doesn't act on GIP at all. Its main practical difference for patients, once approved, would be dosing frequency, not necessarily stronger results.
Can I get a MariTide prescription right now?
No. Outside an active Amgen clinical trial, there's no legal channel to obtain maridebart cafraglutide, and any compounded or gray-market version of it isn't a real or safe option.
Is once-monthly dosing better than once-weekly for weight loss?
Not automatically. Dosing frequency is a convenience factor, not a proven efficacy advantage; the biomarker response, including ApoB, HbA1c, weight, and inflammation markers, determines whether a GLP-1 is working, not how often it's injected.
Does GoodLife Health prescribe MariTide?
No. GoodLife Health's clinical protocols cover only branded, FDA-approved GLP-1 medications: Wegovy, Zepbound, Ozempic, Mounjaro, and Foundayo. MariTide isn't approved, so it isn't part of any current protocol.
What should adults do while waiting for MariTide to be approved?
Start with an approved GLP-1 now, track biomarkers on a fixed schedule, and switch later if MariTide clears FDA review. Waiting without treatment means delaying measurable metabolic change for a drug with no confirmed release date.
One last thing
MariTide's most interesting detail isn't the once-monthly schedule. It's the mechanism. Tirzepatide (Zepbound, Mounjaro) activates the GIP receptor; MariTide blocks it. Two drugs aimed at the same GIP pathway, working in opposite directions, both showing meaningful weight loss in trials. Dosing frequency is the headline in 2026; receptor pharmacology is the actual story, and it's the reason MariTide can't be assumed to behave like a slow-release version of a drug that already exists.
Related guides
- Best GLP-1 medications for weight loss in 2026
- How to get tirzepatide prescribed by a doctor online
- Compounded semaglutide: is it safe and legal in 2026
References
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/